Overview

Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)

Status:
Unknown status

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in the aim to minimize cerebral embolization. But for now, the best antiplatelet regimen has to be determined. In this context, investigators want to evaluate the safety of use of ticagrelor alone versus standardized therapy which involves lysine acetylsalicylate and clopidogrel. In this study, we will randomly compare 154 patients in each group in terms of early safety (30 days) after the procedure.

Phase:

Phase 3

Details

Lead Sponsor:

University Hospital, Bordeaux

Treatments:

Acetylsalicylic acid lysinate
Aspirin
Clopidogrel
Ticagrelor
Ticlopidine